Erica Cecchini

Erica Cecchini

Auto-generated profile, based on publicly available information

Erica Cecchini

Department of Neuropathology University Hospital Erlangen, Friedrich‐Alexander‐Universität Erlangen‐Nürnberg, and partner of the European Reference Network EpiCARE Erlangen Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2025 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
ECErica Cecchini
Erica Cecchini
SGSimon Geffers
Simon Geffers
RCRoland Coras
Roland Coras
DSDorothea Schultheis
Dorothea Schultheis
CHChristian Holtzhausen
Christian Holtzhausen
LHLucas Hoffmann
Lucas Hoffmann
Mild Malformation of Cortical Development with Oligodendroglial Hyperplasia in Epilepsy (MOGHE) is a recently described disease entity primarily affecting young children with drug-resistant epilepsy, mainly affecting the frontal lobe. The condition is histopathologically defined by focal lesions with patchy areas of increased oligodendroglial cell density at the grey-white matter boundary and heterotopic neurons in the white matter. Approximately half of the individuals with MOGHE carry brain somatic variants in the SLC35A2 gene, which affects the UDP-galactose transporter and thus sphingolipid glycosylation. To investigate the impact of SLC35A2 variants on protein expression, we analysed MOGHE brain tissue with and without SLC35A2 mosaicism, distinguishing missense from nonsense variants. We developed an antibody targeting the N-terminus of the SLC35A2 galactose transporter and applied it for immunofluorescence (IF) analyses in a MOGHE cohort comprising 59 genetically tested individuals selected from three centres in Germany. The cohort included 13 individuals with SLC35A2 missense variants and 15 with SLC35A2 nonsense variants. Our findings confirm the localisation of the SLC35A2 protein in the Golgi apparatus of all neuroepithelial cell types as well as within Golgi outposts along oligodendroglial processes. The protein distribution was altered in MOGHE samples dependent on the SLC35A2 variant and its allelic frequency. Western blot and IF analyses revealed a significant SLC35A2 reduction in MOGHE tissues carrying nonsense variants. Ultrastructural analyses from three MOGHE samples demonstrated hypomyelination in regions with increased oligodendroglial cell densities, regardless of the harbouring of SLC35A2 variants. Notably, this hypomyelination pattern decreased with age. These results suggested a role for the SLC35A2 protein in the pathogenesis of MOGHE and indicated the presence of additional myelin-associated pathomechanisms in those individuals who do not carry a pathogenic SLC35A2 variant.

30 May 2026 in Epilepsia
Verified
Journal Article
Open access
ECErica Cecchini
Erica Cecchini
THTill Hartlieb
Till Hartlieb
AGAhmed Gaballa
Ahmed Gaballa
KKKatja Kobow
Katja Kobow
MKMitali Katoch
Mitali Katoch
LHLucas Hoffmann
Lucas Hoffmann
Objective: Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE) is an underrecognized pediatric cortical lesion associated with somatic X‐linked SLC35A2 variants in approximately 50% of individuals. The genetic etiology in individuals without detectable SLC35A2 mutations remains undefined, which limits our understanding of its pathomechanism and clinical characterization. The aim is to identify genetic correlates of MOGHE in individuals lacking pathogenic SLC35A2 variants and to investigate the clinicopathological and genomic correlations. Methods: We investigated archival brain tissue of 29 individuals (19 males, 10 females) with histopathologically confirmed MOGHE. Twenty individuals carried SLC35A2 variants, and nine individuals lacked detectable mutations in SLC35A2 or other epilepsy‐related genes. Brain tissue samples were analyzed using DNA methylation‐derived copy number variation (CNV) analysis, polymerase chain reaction (PCR), and chromogenic/fluorescent in situ hybridization (ISH). Results: CNV analysis identified Y‐chromosomal material in five of 10 females (50%) and mosaic Y‐chromosome gains in 16 of 19 males (84%), confirmed by PCR and ISH, and associated with lesional tissue. Exploratory stratification of the cohort by SLC35A2 status and Y‐chromosome gain revealed a tendency toward earlier seizure onset, multilobar involvement, and cognitive impairment in patients carrying both SLC35A2 mutations and Y‐chromosome gain; however, these differences did not reach statistical significance in our small cohort. Significance: The combined presence of Y‐chromosomal material in females, mosaic Y‐chromosome gains in males, and SLC35A2 variants represents a recurrent genomic feature in patients with MOGHE. These findings suggest that sex‐chromosome anomalies may contribute to the pathobiology of this epilepsy‐associated cortical malformation, highlighting the need to clarify the underlying molecular mechanisms of this clinicohistopathologic entity. Although the root cause, biological consequence, and clinical significance of brain somatic Y‐chromosomal gain remain to be further clarified, our findings identify a previously unrecognized genomic feature of MOGHE and provide a rationale for future research in MOGHE cohorts.